News | October 12, 2021
Everest Organics develops API for molnupiravir
The drug is being developed at lab scale for the first-line of treatment of Covid-19
The drug is being developed at lab scale for the first-line of treatment of Covid-19
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
This opens up a huge market for the company’s Magnezis implants in India
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
The company will use the capital for building its team, product development, marketing, and setting up in-school clinics to deliver connected health to one million families
Subscribe To Our Newsletter & Stay Updated
